TransMedics Group (NASDAQ:TMDX) Research Coverage Started at Robert W. Baird

Robert W. Baird began coverage on shares of TransMedics Group (NASDAQ:TMDX) in a research report report published on Tuesday, Marketbeat reports. The firm issued an outperform rating and a $200.00 price target on the stock.

Several other equities analysts also recently weighed in on TMDX. Cantor Fitzgerald initiated coverage on TransMedics Group in a report on Thursday, June 6th. They set an overweight rating and a $161.00 price target for the company. Oppenheimer raised their price objective on shares of TransMedics Group from $125.00 to $200.00 and gave the company an outperform rating in a research note on Thursday, August 1st. Piper Sandler upped their target price on shares of TransMedics Group from $170.00 to $180.00 and gave the stock an overweight rating in a research note on Thursday, August 1st. Needham & Company LLC assumed coverage on shares of TransMedics Group in a report on Wednesday, August 21st. They set a buy rating and a $208.00 price target on the stock. Finally, Morgan Stanley boosted their price objective on shares of TransMedics Group from $104.00 to $145.00 and gave the stock an equal weight rating in a report on Monday, July 15th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus price target of $174.30.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $144.56 on Tuesday. TransMedics Group has a 12-month low of $36.42 and a 12-month high of $177.37. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. The stock’s 50-day moving average price is $156.02 and its 200-day moving average price is $130.77.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, beating the consensus estimate of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The firm had revenue of $114.30 million during the quarter, compared to the consensus estimate of $98.84 million. During the same period in the prior year, the firm posted ($0.03) earnings per share. The company’s quarterly revenue was up 117.7% compared to the same quarter last year. Sell-side analysts expect that TransMedics Group will post 1.23 EPS for the current year.

Insider Buying and Selling

In related news, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $156.77, for a total transaction of $463,725.66. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at approximately $3,267,557.11. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $8,948,714.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $156.77, for a total transaction of $463,725.66. Following the completion of the sale, the insider now directly owns 20,843 shares in the company, valued at $3,267,557.11. The disclosure for this sale can be found here. Insiders sold a total of 61,247 shares of company stock worth $9,650,880 in the last 90 days. 7.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On TransMedics Group

Hedge funds have recently modified their holdings of the company. Fidelis Capital Partners LLC acquired a new position in TransMedics Group during the first quarter worth $35,000. International Assets Investment Management LLC acquired a new position in shares of TransMedics Group during the 2nd quarter worth about $47,000. J.Safra Asset Management Corp lifted its stake in TransMedics Group by 649.2% in the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after buying an additional 383 shares in the last quarter. Signaturefd LLC boosted its holdings in TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after buying an additional 93 shares during the last quarter. Finally, Amalgamated Bank increased its stake in TransMedics Group by 6.7% during the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after buying an additional 70 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.